Document Detail

JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.
MedLine Citation:
PMID:  20525557     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Multidrug resistance (MDR) is extremely common in hepatocellular carcinoma (HCC) and is a major problem in cancer eradication by limiting the efficacy of chemotherapy. Modulation of c-Jun NH2-terminal kinase (JNK) activation could be a new method to reverse MDR. However, the relationship between JNK activity and MDR in HCC cells is unknown. This study aimed to explore the relationship between MDR and JNK in HCC cell lines with different degrees of MDR. METHODS: A MDR human HCC cell line, SMMC-7721/ADM, was developed by exposing parental cells to gradually increasing concentrations of adriamycin. The MTT assay was used to determine drug sensitivity. Flow cytometry was used to analyze the cell cycle distribution and to measure the expression levels of P-glycoprotein (P-gp) and MDR-related protein (MRP)-1 in these cells. JNK1, JNK2 and JNK3 mRNA expression levels were quantified by real-time PCR. Expression and phosphorylation of JNK1, JNK2, and JNK3 were analyzed by Western blotting. RESULTS: The MDR of SMMC-7721/ADM cells resistant to 0.05 mg/L adriamycin was mainly attributed to the overexpression of P-gp but not MRP1. In addition, these cells had a significant increase in percentage in the S phase, accompanied by a decrease in percentage in the G0/G1 phase, which is likely associated with a reduced ability for cell proliferation and MDR generation. We found that JNK1, JNK2, and JNK3 activities were negatively correlated with the degree of MDR in HCC cells. CONCLUSION: This study suggests that JNK1, JNK2, and JNK3 activities are negatively correlated with the degree of MDR in HCC cells.
Feng Yan; Xiao-Min Wang; Zhong-Chen Liu; Chao Pan; Si-Bo Yuan; Quan-Ming Ma
Related Documents :
11836167 - Actions of the selective protein kinase c inhibitor pkc412 on b-chronic lymphocytic leu...
3500807 - Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracy...
11457647 - Sb203580, a specific inhibitor of p38-mapk pathway, is a new reversal agent of p-glycop...
18937067 - Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain g...
6283827 - The respiratory burst of phagocytic cells: facts and problems.
23321537 - Nise(2) as an efficient electrocatalyst for a pt-free counter electrode of dye-sensitiz...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hepatobiliary & pancreatic diseases international : HBPD INT     Volume:  9     ISSN:  1499-3872     ISO Abbreviation:  HBPD INT     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-07     Completed Date:  2010-09-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101151457     Medline TA:  Hepatobiliary Pancreat Dis Int     Country:  China    
Other Details:
Languages:  eng     Pagination:  287-95     Citation Subset:  IM    
Department of Gastrointestinal Surgery, Zhongshan Hospital, Xiamen University, Xiamen, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / pharmacology
Blotting, Western
Carcinoma, Hepatocellular / enzymology*,  genetics,  pathology
Cell Cycle / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Dose-Response Relationship, Drug
Doxorubicin / pharmacology
Drug Resistance, Neoplasm*
Flow Cytometry
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Inhibitory Concentration 50
Liver Neoplasms / enzymology*,  genetics,  pathology
Mitogen-Activated Protein Kinase 10 / genetics,  metabolism*
Mitogen-Activated Protein Kinase 8 / genetics,  metabolism*
Mitogen-Activated Protein Kinase 9 / genetics,  metabolism*
Multidrug Resistance-Associated Proteins / metabolism
P-Glycoprotein / metabolism*
RNA, Messenger / metabolism
Time Factors
Reg. No./Substance:
0/ABCB1 protein, human; 0/Antibiotics, Antineoplastic; 0/Multidrug Resistance-Associated Proteins; 0/P-Glycoprotein; 0/RNA, Messenger; 0/multidrug resistance-associated protein 1; 23214-92-8/Doxorubicin; EC 2.7.1.-/Mitogen-Activated Protein Kinase 10; EC Protein Kinase 9; EC Protein Kinase 8

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relationship between the expression of IP-10 and IP-10 mRNA in peripheral blood and HBV DNA level in...
Next Document:  Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of ...